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Abstract
Usher syndrome type I (USH1) is an autosomal recessive disorder characterized by congenital profound deafness, vestibular
areflexia and prepubertal retinitis pigmentosa. The first purpose of this study was to determine the pathologic nature of
eighteen USH1 putative splicing variants found in our series and their effect in the splicing process by minigene assays.
These variants were selected according to bioinformatic analysis. The second aim was to analyze the USH1 transcripts,
obtained from nasal epithelial cells samples of our patients, in order to corroborate the observed effect of mutations by
minigenes in patient’s tissues. The last objective was to evaluate the nasal ciliary beat frequency in patients with USH1 and
compare it with control subjects. In silico analysis were performed using four bioinformatic programs: NNSplice, Human
Splicing Finder, NetGene2 and Spliceview. Afterward, minigenes based on the pSPL3 vector were used to investigate the
implication of selected changes in the mRNA processing. To observe the effect of mutations in the patient’s tissues, RNA
was extracted from nasal epithelial cells and RT-PCR analyses were performed. Four MYO7A (c.470G.A, c.1342_1343delAG,
c.5856G.A and c.3652G.A), three CDH23 (c.2289+1G.A, c.6049G.A and c.8722+1delG) and one PCDH15 (c.3717+2dupTT)
variants were observed to affect the splicing process by minigene assays and/or transcripts analysis obtained from nasal
cells. Based on our results, minigenes are a good approach to determine the implication of identified variants in the mRNA
processing, and the analysis of RNA obtained from nasal epithelial cells is an alternative method to discriminate neutral
Usher variants from those with a pathogenic effect on the splicing process. In addition, we could observe that the nasal
ciliated epithelium of USH1 patients shows a lower ciliary beat frequency than control subjects.
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Introduction
Usher syndrome (USH) is an autosomal recessive disorder
characterized by sensorineural hearing loss, retinitis pigmentosa
(RP) and variable vestibular dysfunction. USH is clinically and
genetically heterogeneous and is the most common form of deaf-
blindness of genetic origin, representing 50% of cases [1]. This
disease shows a prevalence of 3.2–6.2/100000 [2], [3], [4].
Three clinical types of USH (types I, II and III; USH1, USH2
and USH3) are recognized, mainly on the basis of the severity and
progression of hearing loss, the age of onset of RP and the
presence of vestibular dysfunction [5].
Usher syndrome type I (USH1) is the most severe form of the
disease and it is characterized by congenital profound deafness,
vestibular areflexia and prepubertal onset of retinitis pigmentosa.
To date, nine loci (USH1B-USH1K) have been mapped and six
genes have been identified: MYO7A (USH1B): MIM#276903;
USH1C (USH1C): MIM# 605242; CDH23 (USH1D): MIM#
605516; PCDH15 (USH1F): MIM# 605514; USH1G (USH1G):
MIM# 607696; and CIB2 (USH1J): MIM# 605564 [reviewed in
6], [7], [8].
Many mutations in MYO7A, USH1C, CDH23, PCDH15 and
USH1G have been identified by several screenings performed in
USH1 patients (http://grenada.lumc.nl/LOVD2/Usher_montpellier/).
The consequences of missense, silent and intronic changes many
times are unknown and additional studies are needed to know
the pathogenicity of these variants.
The use of minigene assays has been shown to be a useful
approach to determine the effect of these variants on the splicing
process, when genes present a restricted expression profile
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(photoreceptors and inner hair cells, in the case of USH) and
human specific tissue samples are difficult to obtain [9].
Cohn et al. [10] demonstrated the presence of eight Usher
proteins in nasal ciliated epithelium using immunochemistry with
fluorescent antibodies. Subsequently, Vache´ et al. [11] provided
evidence that splicing mutations occurring in most USH genes can
be identified through ex vivo analysis of mRNA from nasal
epithelial cells.
On the other hand, the cilium in photoreceptors appears
ultrastructurally and molecularly very similar to the nasal ciliated
epithelium. The cilia are distributed around the human body and
it has been reported that an abnormality in ciliary function may be
linked to the nasal cilia abnormalities, as well as to the retinal
degeneration [12]. There is evidence that immotiles nasal cilial can
be associated with USH1 [13].
In our cohort of patients, we identified different pathogenic
variants and some putative splicing mutations in USH1 genes [14],
[15], [16], [17], [18].
The first purpose of the present work was to determine the
pathogenic nature of selected variants and their effect in the
splicing process by minigene assays. The second aim was to
analyze the USH1 transcripts, obtained from the nasal epithelium
cells of our patients, in order to corroborate the observed effect of
mutations by minigenes in patient’s tissues. The third goal of this
Table 1. Primers used to amplify the specific insert.
Sequence variant Primer Sequence 59-.39 Size (bp)
c.6_9dup (p.L4DfsX39)MYO7A L4DfsX39_D_XhoI AAGAAT CTCGAG AGTGGCTGAGAGAAGAATTC 563
L4DfsX39_R_NheI AAGAAT GCTAGC GGATCCAGAGATGTGTGTAA
c.470G.A (p.S157N) MYO7A S157N_D_XhoI AAGAAT CTCGAG AGACTCCACCTCCCTCTTCA 668
S157N_R_NheI AAGAAT GCTAGC GCTAATGTGAGCTTTGGTAGC
c.640G.A (p.G214R) MYO7A
c.721C.G (p.R241G) MYO7A
G214R & R241G_D_XhoI AAGAAT CTCGAG GAAGGTGAAGGAGAGTGCG 703
G214R & R241G_R_NheI AAGAAT GCTAGC TTCATGGTGGGATTTCCAGC
c.1097T.C (p.L366P)
MYO7A
L366P_D_XhoI AAGAAT CTCGAG TGACATGCTGGAGGGAGTTA 608
L366P_R_NheI AAGAAT GCTAGC CTGACCAAAGCAGGCCAAAA
c.1342_1343delAG (p.S448LfsX2)
MYO7A
S448LfsX2_D_XhoI AAGAAT CTCGAG TCTCCAGGCAGAGGGAACAG 524
S448LfsX2_R_NheI AAGAAT GCTAGC AGCCAGGCTCAGCTGACCTT
c.3508G.A (p.E1170K) MYO7A E1170K_D_XhoI AAGAAT CTCGAG GAGGTGCTTTATGCCCGATG 545
E1170K_R_NheI AAGAAT GCTAGC GAGTGTGGGGAAAAGAGGTG
c.3652G.A (p.G1218R) MYO7A G1218R_D_XhoI AAGAAT CTCGAG ATAGATGGTGGAGCTGAGAG 370
G1218R_R_NheI AAGAAT GCTAGC GCACTGGACACACACACACA
c.5581C.T (p.R1861X) MYO7A R1861X_D_XhoI AAGAAT CTCGAG ACTAGTTGCATCTGGCTGTC 543
R1861X_R_NheI AAGAAT GCTAGC ATCCTGAGCAGCTGCAGGAT
c.1086-12G.A USH1C USH1C_D_XhoI AAGAAT CTCGAG ACAAGCTCGGGGACTTTGCT 438
USH1C_R_NheI AAGAAT GCTAGC ATGGTCTCTGACCCACAGCT
c.2289+1G.A CDH23 c.2289_D_XhoI AAGAAT CTCGAG CAAATATTTCCTCCTCATGG 636
c.2289_R_NheI AAGAAT GCTAGC GCAGGAGAGAAAGTATTTCA
c.6049G.A (p.G2017S) CDH23 G2017_D_XhoI AAGAAT CTCGAG CTTGCTCACCACTCTCATGT 594
G2017_R_NheI AAGAAT GCTAGC GTATCGTCTCCAAGCCTCTT
c.8722+1delG CDH23 c.8722_D_XhoI AAGAAT CTCGAG TTCTGGGCAACACTCCGTGA 1226
c.8722_R_NheI AAGAAT GCTAGC GGATGGACGGATAACTAATGG
c.1304_1305insC PCDH15 c.1304_D_XhoI AAGAAT CTCGAG CAGAAGACTGAAGCAATTAAGCC 647
c.1304_R_NheI AAGAAT GCTAGC ATATACTGAATATCTGCAAGCTG
c.2868+5G.A PCDH15 c.2868_D_XhoI AAGAAT CTCGAG ATTCCAGTGGAACGGCCTTC 533
c.2868_R_NheI AAGAAT GCTAGC TATGCTCTGTACCTGTGGATG
c.3717+2dupTT PCDH15 c.3717_D_XhoI AAGAAT CTCGAG CAGAATTATACCTATGTCCC 635
c.3717_R_NheI AAGAAT GCTAGC AGTGACTAACAATCTGAGTG
c.521A.G (p.N174S) PCDH15 N174S_D_XhoI AAGAAT CTCGAG TTCTTCGCCCATAGCAAGA 605
N174S_R_NheI AAGAAT GCTAGC TGAGGCATATTATACCTATG
c.1737C.G (p.Y579X) PCDH15 Y579X_D_XhoI AAGAAT CTCGAG AGTATTGTAACAGGACACAG 596
Y579X_R_NheI AAGAAT GCTAGC CCTCTGATATTGTCCTCTTC
Tails added at the beginning of the primer are indicated in bold.
Enzyme restriction sites used in this study are indicated in italics.
doi:10.1371/journal.pone.0057506.t001
Study of USH1 Splicing Variants
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study was to evaluate the nasal ciliary beat frequency in eight
USH1 patients and compare it with thirty control subjects.
Materials and Methods
Ethics Statement
This study was approved by the ethic committees of the
Instituto de Investigacio´n Sanitaria IIS-La Fe (Valencia, Spain)
and the General and University Hospital (Valencia, Spain).
Written consent was obtained from all subjects. Clinical investi-
gation was conducted according to the principles expressed in the
Declaration of Helsinki.
Selection of Variants
The first selection of sequence variations for functional studies
was carried out on the following criteria: variants found in a
homozygous state or in trans with a disease-causing mutation,
cosegregation with the disease, not found in 200 control
chromosomes or sequence variation located in exon or introns
that may affect the mRNA processing. All changes have been
characterized in our cohort of patients.
Computational Analysis of Splicing Variants
To analyze the effect of variants in the splice prediction and the
recognition of donor and acceptor sites, in silico analyses were
performed. Four programs were used: Neural Network SPLICE
(NNSplice) 0.9 from the Berkeley Drosophila Genome Project
(available at http://www.fruitfly.org/seq_tools/splice.html), Hu-
man Splicing Finder (HSF)-Version 2.4 (available at http://www.
umd.be/HSF/), NetGene2 (available at http://www.cbs.dtu.dk/
service/NetGene2/) and Spliceview (available at http://zeus2.itb.
cnr.it/˜webgene/wwwspliceview_ex.html).Score-values were cal-
culated taking into account the bioinformatic predictions, from 1
to 4, depending on how many of the four programs have predicted
changes on the splice sites.
Minigene Constructions and Expression
Minigene constructions based on the pSPL3 exon trapping
vector (kindly provided by Dr. I Botillo and Dr. S. Tuffery-Giraud)
were used to investigate the implication of selected variants on the
mRNA processing. These variants were selected based on the
bioinformatic predictions.
For these putative splicing variants, the exon and intronic
flanking sequences were amplified from the patient’s DNA, using
the High Fidelity Phusion polymerase (Finnzymes, Espoo, Finland)
with primers detailed in Table 1. Amplicons were inserted
between the XhoI/NheI restriction sites, using T4 DNA ligase
(Invitrogen Corporation, Carlsbad, CA). We only could obtain the
wild type (WT) insert for the variant c.3717+2dupTT (PCDH15)
and the mutant insert for changes c.3652G.A and c.5581C.T
(MYO7A), c.1086-12G.A (USH1C), c.8722+1delG (CDH23) and
c.1304_1305insC, c.2868+5G.A and c.1737C.G (PCDH15).
The corresponding WT or mutant insert was obtained by site-
directed mutagenesis using primers detailed in Table 2. Minigene
constructions were confirmed by direct sequencing in both
directions with BigDye Terminator 3.1 cycle sequencing kit from
Applied Biosystems (Carlsbad, USA). Sequence reactions were
analyzed on a capillary ABI 3500xl Genetic Analyzer (Applied
Biosystems) according to the manufacturer’s instructions. After-
wards, minigenes were transfected into COS-7 cells as described
before by Jaijo et al. [19]. RNA extraction and RT-PCR analysis
was performed as previously described [20], [21]. All experiments
were performed in duplicate.
Nasal Epithelial Cells Samples from Controls and Patients
A total of thirty-eight fresh nasal samples were obtained from
eight USH1 patients, five patients with mutations in MYO7A gene
and three patients with mutations in the CDH23 gene, and thirty
control subjects. The nasal samples were obtained from the middle
nasal concha using curettage without local anesthesia, in a period
during which acute infection was absent [12], in the ENT service
of the Hospital General de Valencia, Spain.
Table 2. Primers used for the site-directed mutagenesis.
Sequence variants Primer Sequence 59-.39
c.3717+2dupTT PCDH15 WT c.3717-D-WT GCAAAGCCGATGTACTCGT-AAGTAGATAAAACTTCAGG
c.3717-R-WT CCTGAAGTTTTATCTACTT-ACGAGTACATCGGCTTTGC
c.5581C.T (p.R1861X) MYO7A MUT R1861X-D-MUT GCTTCCTGCAGTCCCGAAAGCACTGCCCA
R1861X-R-MUT TGGGCAGTGCTTTCGGGACTGCAGGAAGC
c.3652G.A (p.G1218R) MYO7A MUT G1218R-D-MUT AACTTCATCCACAGGGGCCCGCCCG
G1218R-R-MUT CGGGCGGGCCCCTGTGGATGAAGTT
c.1086-12G.A USH1C MUT c.1086-D-MUT CCAGTAACAGGCATGGGGATCTCATTTTAGGATTGTAG
c.1086-R-MUT CTACAATCCTAAAATGAGATCCCCATGCCTGTTACTGG
c.8722+1delG CDH23 MUT c.8722-D-MUT GGTCTTCACCATGG-TAGGGCCTGGCAGC
c.8722-R-MUT GCTGCCAGGCCCTA-CCATGGTGAAGACC
c.1304_1305insC PCDH15 MUT c.1304-D-MUT GTAGCTCTGGACAAGGACATAGAAGACTGTAAGTTAAATACATATTTTGC
c.1304-R-MUT GCAAAATATGTATTTAACTTACAGTCTTCTATGTCCTTGTCCAGAGCTAC
c.2868+5G.A PCDH15 MUT c.2868-D-MUT GAAGATGCAGACCCTCCTGTAAATAGAAGGCATTGATTAATATT
c.2868-R-MUT AATATTAATCAATGCCTTCTATTTACAGGAGGGTCTGCATCTTC
c.1737C.G (p.Y579X) PCDH15 MUT Y579X-D-MUT TGATAGTCGGGCGGACTTAGGCACTCACGG
Y579X-R-MUT CCGTGAGTGCCTAAGTCCGCCCGACTATCA
The nucleotides that have been modified are indicated in bold.
The positions of deleted nucleotides are represented with (2).
doi:10.1371/journal.pone.0057506.t002
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RNA and Sequence Analysis
RNA extraction from nasal epithelial cells and RT-PCR
analysis was performed as previously described [11]. cDNA was
used as template in nested PCR reactions with specific primers in
order to amplify the regions containing the mutation (Table 3).
PCR products were tested on 1.5% agarose gel and purified by
ExoSAP. PCR products were sequenced and analyzed. All
experiments were performed in duplicate.
Nomenclature of Variants
The sequences obtained were compared with the consensus
sequence NM 000260.3 for MYO7A, NM 153676.2 for USH1C,
NM 022124.3 for CDH23 and NM 033056.3 for PCDH15.
For the protein nomenclature, we used the Mutalyzer 2.0 beta-
21 program (available at https://mutalyzer.nl/).
Nasal Ciliary Beat Frequency
Ciliary beat frequency was measured as described by Armengot
et al. [12] in eight USH1 patients and thirty healthy subjects. The
beat pattern was observed using high-resolution digital high-speed
video imaging. Values were expressed in Hertz (Hz) as the mean 6
standard error of mean.
Statistical Analysis
Ciliary beat frequencies were analyzed by Kruskal-Wallis test
followed by Dunns post-hoc test. When only two groups were
compared, Mann-Whitney U test was used. Significance levels were
set at p,0.05. Data were analyzed with statistical analysis software
GraphPad Prism (Version 5.01, San Diego, USA).
Results
Computational Analysis
One hundred and eight variants identified in the USH1 genes
were studied with bioinformatic tools (SpliceView, NNSplice, NetGene2
and HSF) in order to analyze the effect of these variants in the
splice prediction and the recognition of donor and acceptor sites.
Nine MYO7A, three CDH23, five PCDH15 and one USH1C
variants were predicted to alter the splicing mechanism creating or
eliminating donor/acceptor splice sites, see table 4. Considering
the four programs (Splice View, NNSplice, NetGene2 and HSF) the
score-values were calculated. Eight out of the eighteen variants
showed the highest score (4), five of them showed a score of 3, two
of the variants were observed to show a score of 2 and the three
remaining changes showed a score of 1.
Minigene Constructions
In order to confirm the bioinformatic predictions, minigenes
were constructed and the different splicing products were
analyzed. The minigene assays showed that only seven of them
were affecting the mRNA processing: three MYO7A variants,
c.470G.A, c.1342_1343delAG and c.3652G.A, three CDH23
changes, c.2289+1G.A, c.6049G.A and c.8722+1delG, and one
PCDH15 variant, c.3717+2dupTT, see Table 5.
c.470G.A (p.S157N, MYO7A). The minigene assay showed
that the processing of the WT minigene generated two main
fragments: the correct processing (band A) and the exon skipping
(band B). The mutant minigenes only showed one fragment
corresponding to the skipping of exon 5 (band B) (Fig. 1A). If this
mutant transcript was translated, it would produce a truncated
protein of only 123 amino acids in length, p.T96WfsX29.
c.1342_1343delAG (p.S448LfsX2, MYO7A). In vitro analy-
ses confirmed that the WT transcript contained the correct exon
(band A) but the c.1342_1343delAG construction generated
several bands. We were only able to sequence band B that
corresponded to the exon 12 with a partial deletion. The mutation
removed the main donor site and created a new donor splice-site
leading to a deletion of 24-bp (Fig. 1B). Thus, the new myosin
VIIA protein generated, if this aberrant transcript was translated,
it would be of 2207 amino acids in length, p.N443_E450del.
c.3652G.A (p.G1218R, MYO7A). In vitro experiments
showed that WT minigene generated two different transcripts:
one of them corresponded to the correct transcript (band A) and
the smallest and strongest transcript was the skipping of exon 29
(band B). A third band (band C) was also observed corresponding
to the heteroduplex formation from the two obtained transcripts.
Mutant minigene only showed one transcript corresponding to the
aberrant splicing process (band D). This mutation avoided the
recognition of the main acceptor site and created a new acceptor
splice-site leading to a deletion of 103-bp in the 59 end of exon 29
Table 3. Primers used to amplify fragments of MYO7A and
CDH23 cDNAs from nasal cells.
Gene Exons Primers Sequence 59-.39
Size
(bp)
MYO7A 1–5 MYO_EXP_1-5-EXT-D AGAGACAAGAGACACACACA 628
MYO_EXP_1-5-EXT-R CTTCTTGTTGGTATACTGGC
MYO_EXP_1-5-INT-D TAGAACGAGACTTGGAGCCA 490
MYO_EXP_1-5-INT-R TTCACAGCCACCAGGATGGA
3–9 MYO_EXP_3-9-EXT-D ACCATGTGTGGATGGACCTG 937
MYO_EXP_3-9-EXT-R CTTCGAGATCTCCCAGTTCT
MYO_EXP_3-9-INT-D ACTCTGGGCAGGTCCAGGT 806
MYO_EXP_3-9-INT-R TGTTGGCGTACTCCTGGCT
8–14 MYO_EXP_8-14-EXT-D TGTTCTACTGCATGCTGGAG 906
MYO_EXP_8-14-EXT-R CCTGCAAAATGGTTGATGCC
MYO_EXP_8-14-INT-D AAGAAGAAGCTGGGTTGGG 811
MYO_EXP_8-14-INT-R TTGGCGTTGAGCTTGTGCT
25–33 MYO_EXP_25-33-EXT-D ATGAGACCCTGGGCAAGAAG 1136
*MYO_EXP_25-33-EXT-
R
CTTCTGGGCATCAGTTCTCC
MYO_EXP_25-33-INT-D AGGGCCAGAAGAAGAGCAGT 924
MYO_EXP_25-33-INT-R CGCTCCAGGATCATCTCAGA
38–45 MYO_EXP_38-45-EXT-D TCCTATGACTACTTCAGGCC 1010
MYO_EXP_38-45-EXT-R GGGGAAGTAGGACTTGTCCT
MYO_EXP_38-45-INT-D TCAAGCAGGCGCTGCTCAAGA 835
MYO_EXP_38-45-INT-R CGTGCACTTGTGGTAGCCTC
CDH23 18–24 CDH_EXP_18-24-EXT-D ATGAACAGATATCCAATGGGC 790
CDH_EXP_18-24-EXT-R GGTTCTGAAAGGTGGGGTCA
CDH_EXP_18-24-INT-D AATGACAACCCTCCCACCTT 627
CDH_EXP_18-24-INT-R CACTGCTGGTGGCTTTCAGA
43–49 CDH_EXP_43-49-EXT-D CATCAACGACAACGACCCTGT 1084
CDH_EXP_43-49-EXT-R GGTTGAGGTCGTGGTCAATG
CDH_EXP_43-49-INT-D TCTGTGAAGGACAACCCGGA 708
CDH_EXP_43-49-INT-R GAATGGTGACAATGGCTGTG
57–63 CDH_EXP_57-63-EXT-D CTCATCTTGGTGGCCAGCGAC 1015
CDH_EXP_57-63-EXT-R CCGGCAGCCGGACAGAGAT
CDH_EXP_57-63-INT-D TTCATCGTCAAGGCCTCCAG 713
CDH_EXP_57-63-INT-R TAGCTGCTCCTTGTTCTCA
*The primer MYO_EXP_25-33-EXT-R was designed by Vache´ et al. [11].
doi:10.1371/journal.pone.0057506.t003
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(Fig. 1C). If the c.3652G.A transcript was translated, it would
generate a new truncated protein of 1227 amino acids in length,
p.Y1211AfsX18.
c.2289+1G.A (CDH23). The WT minigene generated a
strong band corresponding to the correct transcript (band A) and a
thin band corresponding to the exon skipping (band B). The
mutant minigene showed two strong bands; one of them was the
transcript with the exon 21 plus part of the intron 21 (band C) and
the other band was the exon skipping (band B). This variant
generated two different transcripts: one of them did not recognize
the main donor site and created a new donor site including the first
149 nucleotides of intron 21 and the other transcript produced the
skipping of exon 21. Thus, c.2289+1G.A would create two
different proteins; p.N765SfsX35, of 798 amino acids in length,
would correspond to the exon 21 plus 149 nucleotides of intron 21,
and the other new truncated protein would be p.E727KfsX9, of
734 amino acids in length (Fig. 1D).
c.6049G.A (p.G2017S, CDH23). Minigene assays revealed
that the WT construction created two different transcripts: one of
them corresponded to the correct transcript (band A) and the
smallest transcript was the skipping of exon 46 (band B). A third
band was also observed corresponding to the heteroduplex
formation from the two smaller transcripts (band C). However,
the c.6049G.A construction only showed one band correspond-
Table 4. Results from four different bioinformatic programs used to predict the effect on the splicing process.
Sequence variants
Type of
splice
site NetGene2 HSF NNSplice Splice View Score
c.6_9dup (p.L4DfsX39)
MYO7A [14]
Acceptor Score for acceptor site
increases from 77 to 82
The WT consensus sequence
is not recognized
One donor site is not
recognized
New acceptor sites are
created and other
acceptor sites are not
recognized
3
c.470G.A (p.S157N)
MYO7A [14]
Donor Score for the main donor
site decreases from 93 to 60
Score for donor site decreases
and a new acceptor site is
created
The main donor site is
not recognized
The main donor site is
not recognized
4
c.640G.A (p.G214R)
MYO7A [22]
Acceptor Neutral The WT consensus sequence
is not recognized
A new acceptor site is
created
Neutral 1
c.721C.G (p.R241G)
MYO7A [15]
Donor Three new donor site
are created
A new acceptor site
is created
Score for the main
acceptor site decreases
from 81 to 59
A new donor site is
created
4
c.1097T.C (p.L366P)
MYO7A [15]
Acceptor Score for the main acceptor
site decreases from 83 to 77
Score for the acceptor
site decreases
A new acceptor site is
created
Neutral 3
c.1342_1343delAG
(p.S448LfsX2)
MYO7A [14]
Donor The main donor site is not
recognized
The main donor site and the
acceptor site are
not recognized
The main donor site is
not recognized
The main donor site is
not recognized
4
c.3508G.A (p.E1170K)
MYO7A [23]
Acceptor Score for the main acceptor
site decreases from 85 to 77
Neutral Neutral Neutral 1
c.3652G.A (p.G1218R)
MYO7A [15]
Acceptor A new acceptor site
is created
A new acceptor site
is created
A new acceptor site is
created
A new acceptor site is
created
4
c.5581C.T (p.R1861X)
MYO7A [22]
Acceptor Score for the main acceptor
site decreases from 77 to 72
Neutral Neutral Neutral 1
c.1086-12G.A
USH1C [17]
Acceptor A new acceptor site
is created
Score for acceptor site
decreases
Score for the main
acceptor site decreases
from 48 to 45
The main acceptor site is
not recognized
4
c.2289+1G.A
CDH23 [24]
Donor The main donor site is
not recognized
The main donor site is not
recognized
The main donor site is
not recognized
The main donor site is
not recognized
4
c.6049G.A (p.G2017S)
CDH23 [25]
Donor Neutral The main donor site is not
recognized
The main donor site is
not recognized
Score for the main
donor site decreases
from 89 to 84
3
c.8722+1delG
CDH23 [16]
Donor Neutral The main donor site is not
recognized
The main donor site is
not recognized
The main donor site is
not recognized
3
c.521A.G (p.N174S)
PCDH15 [18]
Acceptor Score for the main acceptor
site decreases from 92 to 87
The main acceptor site is
not recognized
Neutral Neutral 2
c.1304_1305insC
(p.T436YfsX12)
PCDH15 [18]
Donor Score for the main donor
site decreases from 63 to 51
The WT consensus sequence
is not recognized
Score for the main
donor site decreases
from 99 to 94
Score for the main donor
site decreases from 81 to
79
3
c.1737C.G (p.Y579X)
PCDH15 [18]
Donor Score for the main donor
site decreases from 52 to 37
The main donor site
is not recognized
Neutral Neutral 2
c.2868+5G.A
PCDH15 [18]
Donor The main donor site is not
recognized and a new
donor site is created
The main donor site
is not recognized.
The main donor site is
not recognized.
The main donor site is
not recognized.
4
c.3717+2dupTT PCDH15
Present study
Donor The main donor site is
not recognized
The main donor site
is not recognized
The main donor site is
not recognized
The main donor site is
not recognized
4
doi:10.1371/journal.pone.0057506.t004
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ing to the skipping of exon 46 (band B) (Fig. 1E). If the transcript
containing the c.6049G.A variant was translated, it would
generate a protein of 3312 amino acids in length,
p.T1976_G2017del.
c.8722+1delG (CDH23). In vitro experiments showed that the
WT construction generated one band (band A) corresponding to
the correct transcript and the mutant construction showed a band
with apparently the same size of the correct transcript (band B).
However, when these fragments were sequenced, we could
observe that the two fragments were different. The mutation
produced the displacement of the donor splice site one nucleotide
upstream, being the last nucleotide of the exon 60 processed as
intron (Fig. 1F). If this mutant transcript was translated, it would
be generating a new truncated protein of 2950 amino acids in
length, p.S2909AfsX43.
c.3717+2dupTT (PCDH15). In our series of patients, we
identified a novel variant in intron 27 of the PCDH15 gene in one
Spanish USH1 family in homozygous state. We confirmed by
Table 5. Effects of USH1 variants on splicing.
Putative splicing
variants
Score
according to
bioinformatic
tools
Effect on RNA level according to
minigene results
Effect on protein
level according
to minigene
results
Effect on RNA level
according to nasal cells
results
Effect on protein
level according
to nasal cells
results
c.6_9dup (p.L4DfsX39)
MYO7A
3 No effect on splicing p.L4DfsX39 No effect on splicing p.L4DfsX39
c.470G.A (p.S157N)
MYO7A
4 Exon skipping p.T96WfsX29 – –
c.640G.A (p.G214R)
MYO7A
1 No effect on splicing p.G214R No effect on splicing p.G214R
c.721C.G (p.R241G)
MYO7A
4 No effect on splicing p.R241G – –
c.1097T.C (p.L366P)
MYO7A
3 No effect on splicing p.L366P – –
c.1342_1343delAG
(p.S448LfsX2) MYO7A
4 The mutation removes the main donor
site and creates a new donor splice-site
leading to a deletion of 24bp
p.N443_E450del – –
c.3508G.A (p.E1170K)
MYO7A
1 No effect on splicing p.E1170K No effect on splicing p.E1170K
c.3652G.A (p.G1218R)
MYO7A
4 The mutation does not recognize the acceptor
site and a new acceptor splice-site is created
leading to a deletion of 103-bp in the 59
end of exon 29
p.Y1211AfsX18 – –
c.5581C.T (p.R1861X)
MYO7A
1 No effect on splicing p.R1861X No effect on splicing p.R1861X
*c.5856G.A (p.K1952K)
MYO7A
4 Exon skipping p.A1915_K1952del Exon skipping p.A1915_K1952del
c.1086-12G.A USH1C 4 No effect on splicing Neutral – –
c.2289+1G.A CDH23 4 This variant does not recognize the main donor
site and a new donor splice-site is created
inserting the first 149 nucleotides of intron
21+ Exon skipping
p.N765SfsX35+
p.E727KfsX9
Transcript with an insertion
of the first 149 nucleotides
of intron 21 plus the last 54
nucleotides of the same
intron
p.N765SfsX35
c.6049G.A (p.G2017S)
CDH23
3 Exon skipping p.T1976_G2017del Probable NMD -
c.8722+1delG CDH23 3 Deletion of the last nucleotide of exon 60 p.S2909AfsX43 Deletion of the last
nucleotide of exon 60
p.S2909AfsX43
c.521A.G (p.N174S)
PCDH15
2 No effect on splicing p.N174S – –
c.1304_1305insC
(p.T436YfsX12) PCDH15
3 No effect on splicing p.T436YfsX12 – –
c.1737C.G (p.Y579X)
PCDH15
2 No effect on splicing p.Y579X – –
c.2868+5G.A PCDH15 4 No effect on splicing Neutral – –
c.3717+2dupTT PCDH15 4 c.3717+2dupTT does not recognize the main
donor site and creates a new donor splice-site
that includes the first 52 nucleotides of
intron 27+ Exon skipping
p.V1242RfsX2+
p.A1168_L1239del
– –
Not performed in this study are indicated with (2).
NMD: Nonsense mediated decay.
*c.5856G.A (p.K1952K, MYO7A) was previously analyzed by Jaijo et al. [26].
doi:10.1371/journal.pone.0057506.t005
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Figure 1. In vitro splicing assays for the seven splicing mutations identified in the USH1 genes. Gel electrophoresis shows the different
splicing processes for WT minigene and mutants constructions. COS-7 cell transfection experiments were performed in duplicate. A. c.470G.A
(p.S157N, MYO7A). Band A is the correct transcript of exon 5 (MYO7A). Band B is the skipping of involved exon. B. c.1342_1343delAG
(p.S448LfsX2, MYO7A). Band A is the correct transcript corresponding to the exon 12 (MYO7A). Band B is the skipping of exon 12. C. c.3652G.A
(p.G1218R MYO7A). Band A is the correct transcript of exon 29 (MYO7A). The band B is the exon skipping. Band C is the heteroduplex formation
from band A and band B. Band D is the aberrant splicing process that include the deletion of 103-bp of 59end of exon 29. D. c.2289+1G.A
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minigene assays that the WT construction generated one correct
fragment (band A). However, the c.3717+2dupTT minigene
showed two different transcripts: the smallest and strongest
transcript corresponded to the skipping of exon 27 (band B) and
transcript containing exon 27 plus part of intron 27 (band C). A
bigger band was observed corresponding to the heteroduplex from
the two transcripts (band D). This novel mutation generated two
different transcripts: the smallest and strongest transcript that
corresponded to the skipping of involved exon 27 and a second
transcript corresponding to the no recognition of the main donor
splice site and the creation of a new donor site that includes the
first 52 nucleotides of intron 27 (Fig. 1G). Therefore, the mutation
would be creating two different proteins; one of them, corre-
sponding to the skipping of exon 27, would create an in-frame
deletion of 72 amino acids in length, p.A1168_L1239del, and a
new truncated protein, corresponding to the exon 27 plus the first
52 nucleotides of intron 27, of 1241 amino acids in length,
p.V1242RfsX2.
Nasal Epithelial Cells
To carry out the second goal of the present study, we designed
different primers to amplify particular fragments of the MYO7A
and CDH23 cDNAs from the nasal epithelium cells of patients and
controls, in order to corroborate the observed effect of mutations
by minigenes in the patient’s tissues. We only could obtain samples
from subjects carriers of eight of the nineteen variants analyzed
in vitro by minigenes. These samples were obtained from five
USH1 patients and two family healthy carriers of the mutations
c.6_9dup (RP-1481) and c.640G.A (RP-1546) in the MYO7A
gene (Table 6).
Only in four of the eight studied variants (c.5856G.A in the
MYO7A gene, c.2289+1G.A, c.6049G.A and c.8722+1delG in
the CDH23 gene), we could observe an abnormal splicing process
ex vivo (Table 5). In the remaining four samples both WT and
mutant alleles were amplified showing that the presence of the
mutations did not affect the splicing process.
c.5856G.A (p.K1952K, MYO7A). Jaijo et al. [26] analyzed
the c.5856G.A variant by minigene constructions. It showed the
skipping of exon 42. The analysis of this change in the patient RP-
280 replicate 1 revealed the presence of two transcripts: a fragment
corresponding to the expected size, 835-bp also in the control
sample (band A), and a fragment of 721-bp (band B). However, in
the patient’s replicate 2, we only could amplify the smallest
fragment. Sequencing of the products showed that the fragment of
835-bp corresponded to the normal allele. However, the product
of 721-bp was the transcript without exon 42; if the transcript
containing the p.K1952K variant was translated, it would create a
new protein of 2177 amino acids in length, p.A1915_K1952del
(Fig. 2A).
c.2289+1G.A CDH23. xamination of the RT-PCR product
of the patient RP-1534 showed the presence of two transcripts,
band A (observed in the replicate 2) and band B (observed in the
replicate 1). However, in the control sample only one transcript
was observed (band A). Sequencing of the band A showed the
correct transcript of 627-bp. The patient’s replicate 1 amplified an
abnormal transcript that included the first 149 nucleotides of
intron 21 and the last 54 nucleotides of the same intron (band B)
(Fig. 2B). Therefore, the mutation would be creating a new
truncated protein of 798 amino acids in length, p.N765SfsX35.
c.6049G.A (p.G2017S, CDH23). The patient RP-1534 also
carried the p.G2017S. In this case, we only could amplify and
sequence the normal allele (Fig. 2C).
c.8722+1delG (CDH23). Analysis of the RT-PCR product of
patient RP-928 showed only one band. However, sequencing
clearly revealed the presence of two distinct transcripts: a normal
spliced transcript and an abnormal transcript in which the splice
site is modified causing the removal of one nucleotide (G) in the
exons 60 and 61 boundary (Fig. 2D). Thus, if this mutant
transcript was translated, the new protein would be of 2950 amino
acids in length, p.S2909AfsX43.
Ciliary Beat Frequency
The ciliary beat frequencies obtained from each patient and
control were summarized in Table 7. Ciliary beat pattern was
normal in all the patients. We analyzed whether USH1 patients
showed differences in ciliary beat frequency compared to controls.
As shown in Fig. 3A, the ciliary beat frequency was significantly
(CDH23). Band A is the normal transcript of exon 21 (CDH23). Band B is the skipping of exon 21. Band C is the aberrant splicing process that includes
the first 149 nucleotides of intron 21. E. c.6049G.A (p.G2017S, CDH23). Band A is the correct transcript of exon 46 (CDH23). Band B is the skipping
of exon 46. Band C is the heteroduplex formation from the band A and B. F. c.8722+1delG (CDH23). Band A is the correct splicing process of exon
60 (CDH23). Band B is the abnormal splicing process of exon 60 that shows a deletion of the last nucleotide (G) of the involved exon. G.
c.3717+2dupTT (PCDH15). Band A is the correct transcript of exon 27 (PCDH15). Band B is the skipping of the involved exon. Band C is the
transcript corresponding to the new donor splice site from exon 27 plus the first 52 nucleotides of the intron 27. Band D is the heteroduplex
formation from the band B and the band D.
doi:10.1371/journal.pone.0057506.g001
Table 6. Genotypes of the five USH1 patients and the two family healthy carriers of USH1 mutations presented in this study.
Patient Gene Allele 1/Allele 2
RP-1481* MYO7A c.6_9dup (p.L4DfsX39) (exon2)/+
RP-1546* MYO7A c.640G.A (p.G214R) (exon7)/+
RP-115 MYO7A c.3508G.A (p.E1170K) (exon 28)/c.3238A.T (p.K1080X) (exon 25)
RP-1479 MYO7A c.5581C.T (p.R1861X) (exon 40)/c.5581C.T (p.R1861X) (exon 40)
RP-280 MYO7A c.5856G.A (p.K1952K) (exon 42)/c.1190C.A (p.A397D) (exon 11)
RP-1534 CDH23 c.2289+1G.A (intron 21)/c.6049G.A (p.G2017S) (exon46)
RP-928 CDH23 c.8722+1delG (intron 60)/c.6511delC (exon48)
Family healthy carriers are indicated with an asterisk (*).
doi:10.1371/journal.pone.0057506.t006
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reduced in these patients (9.6860.49 Hz, Mann Whitney U test,
p = 0.031) compared to controls (10.8860.25 Hz).
We also evaluated whether ciliary beat frequency were different
between MYO7A and CDH23 patients. No statistical differences
were found between MYO7A patients (10.2060.66 Hz) and
CDH23 patients (8.8360.44 Hz, Kruskal-Wallis test followed by
Dunns test). However, nasal ciliary beat frequency was signifi-
cantly lower in CDH23 patients than in controls (p,0.05, Kruskal-
Wallis Test followed by Dunns test) (Fig. 3B).
Discussion
A high number of mutations responsible for USH have been
identified by screenings performed in USH patients. The effect of
variants that lead to premature stop codons is not questioned;
however, it is complicated to predict the consequences of missense,
Figure 2. Transcript analysis of USH1 variants in nasal
epithelial cells. Gel electrophoresis shows the RT-PCR products
obtained for USH1 patients and control samples. Electropherograms of
the transcripts obtained show the molecular characterization of the
effect of the studied variants. All experiments were performed in
duplicate. A. c.5856G.A (p.K1952K, MYO7A). Band A is the correct
splicing process of the exons 38–45 of the MYO7A gene. Band B is the
skipping of exon 42. RP-280 replicate 1 shows two transcripts
corresponding to the WT allele (band A) and mutant allele (band B).
RP-280 replicate 2 shows only the band B corresponding to the
aberrant transcript. B. c.2289+1G.A (CDH23). Band A is the transcript
corresponding to the normal RNA processing of the exons 18–24 of the
CDH23 gene. Band B is the aberrant transcript that includes the first 149
nucleotides and the last 54 nucleotides of intron 21. C. c.6049G.A
(p.G2017S, CDH23). RP-1534 shows only the WT allele. D.
c.8722+1delG (CDH23). RP-928 shows the heterozygous transcript
from WT allele and the mutant allele. It presents a deletion of the last
nucleotide (G) of exon 60 of CDH23 gene.
doi:10.1371/journal.pone.0057506.g002
Figure 3. Nasal ciliary beat frequency in five MYO7A and three
CDH23 patients, and thirty controls. A. Comparison between USH1
group and Control group. The nasal ciliary beat frequency was
significantly different between these groups (Mann Whitney Test, p
= 0.031). B. Comparison between the MYO7A group and CDH23 group,
MYO7A and Control group and CDH23 group and Control group. The
nasal ciliary beat frequency was significantly different between CDH23
group and Control group (P,0.05).
doi:10.1371/journal.pone.0057506.g003
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silent and intronic changes, in order to discriminate neutral
variants from those with pathogenic effect. Variants putative to
affect the splicing process are usually considered pathogenic on the
basis of their conservation in the canonical splice site, their absence
in control samples, cosegregation with the disease in families and
results from bioinformatic predictions [26].
Four bioinformatic programs (NNSplice, SpliceView, HSF and
NetGene2) were used to predict the damaging effect of the variants
identified in the USH1 genes of our cohort and eighteen changes
were selected as putative to affect the splicing process (Table 4).
These results are only computational predictions so, additional
studies are necessary to confirm the effect on the mRNA
processing. Minigenes and RNA assays were performed to achieve
this goal.
Minigene assays revealed that only seven of the eighteen studied
variants were affecting the splicing process (Table 5). The
bioinformatic analysis of these seven variants had shown high
scores. A maximum score of 4, for five of them: c.470G.A,
c.1342_1343delAG and c.3652G.A in the MYO7A gene,
c.2289+1G.A in CDH23 gene and c.3717+2dupTT in PCDH15
gene. The other two variants (c.6049G.A and c.8722+1delG in
the CDH23 gene) showed a score of 3. However, other studied
variants that also reached a high score ($3) did not show any effect
in the splicing process when they were analyzed by minigenes.
According to these results, all types of putative pathogenic variants
should be analyzed by bioinformatic tools, and, when high scores
are observed, minigene analysis should be performed to avoid false
positive. See Table 5.
However, the splicing processes observed by minigenes would
not necessarily reflect the real processing in affected tissues. In our
study, we could analyze RNA from nasal epithelial cells from
patients or carriers of eight variants previously analyzed by
minigene constructions, to determine their effect on splicing
process in patient’s tissues. Analysis of the RT-PCR amplification
of nasal cells allowed us to confirm that four of the eight studied
variants, one MYO7A (c.5856G.A) and three CDH23
(c.2289+1G.A, c.6049G.A and c.8722+1delG), were affecting
the splicing process. The same results were obtained by minigene
constructions for the eight studied variants, except for two CDH23
changes, c.2289+1G.A and c.6049G.A.
For the c.2289+1G.A variant the different results obtained by
both methods are due to the minigene construction did not
contain the entire intron 21 of the CDH23 gene.
In the study of the c.6049G.A variant by analysis of RT-PCR
amplification from nasal cells we were not able to amplify the
mutant transcript. This fragment could be degraded by nonsense
mediated decay mechanism (NMD), decreasing the mRNAs levels
and therefore, the protein levels. However, by minigene construc-
tion we had observed in this case the skipping of exon 46.
In three cases (c.5856G.A (MYO7A), c.2289+1G.A (CDH23)
and c.6049G.A (CDH23)), we could only amplify one of the two
alleles due to the low USH1 genes expression level in this tissue. In
fact, these USH transcripts are only detectable by nested PCR.
Accordingly, it is advisable to detect the presence of heterozygous
changes by sequencing, the studied mutation or other SNPs, to
confirm the amplification of the two alleles and avoid incorrect
conclusions when apparently only one fragment is obtained after
PCR.
Therefore, minigenes are a good approach to ascertain the
pathogenic nature of splice variants when is difficult to obtain
RNA from patients’ tissues, as in the case of USH genes, that
present a restricted expression profile associated with photorecep-
tors and inner hair cells. These constructions are expressed in
living cells where the splicing machinery remains intact.
In addition, we can confirm that the analysis of nasal epithelial
cells is an alternative method to discriminate neutral Usher
Table 7. Nasal ciliary beat frequency of USH1 patients and
controls.
MYO7A patients Nasal Ciliary Beat Frequency (Hz)
1 8.5
2 12
3 11.5
4 9.5
5 9.5
CDH23 patients Nasal Ciliary Beat Frequency (Hz)
1 8
2 9
3 9.5
Control subjects Nasal Ciliary Beat Frequency (Hz)
1 11.58
2 10
3 10
4 12
5 11.35
6 10.2
7 13
8 9
9 10.6
10 12.3
11 11
12 12
13 12.5
14 10.8
15 9.1
16 14
17 10.7
18 9.5
19 9.5
20 11.8
21 11
22 9.5
23 9
24 10.8
25 14
26 9.75
27 9.75
28 11.75
29 10.5
30 10.5
Disease Group Nasal ciliary beat frequency (Hz), mean 6 SD
MYO7A (n = 5) 10.2061.44
CDH23 (n = 3) 8.3360.76
USH1 (n = 8) 9.6861.38
Control (n = 30) 10.8861.36
doi:10.1371/journal.pone.0057506.t007
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variants from those with a pathogenic effect on the splicing
process.
Finally, we have also demonstrated that the nasal ciliated
epithelium of USH1 patients has a lower ciliary beat frequency
than control subjects. Armengot et al. [12] suggested that
mutations in the USH1 and USH2 genes could be responsible
for the lower ciliary beat frequency. They observed a low beat
frequency in USH2 patients. However, the ciliary activity was
sufficient to operate normally and no clinical consequences were
observed in these patients.
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